MedTrace Logo

Detect and Expunge Concealed Tumors of the Liver

NCT06141564 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2025-11-18

No results posted yet for this study

Summary

The investigators long-term goal is to identify molecular and immunological signatures that can be used as biomarkers to accurately predict early recurrence and inform immunotherapeutic strategies in patients with hepatocellular carcinoma (HCC) after hepatectomy. As an initial step toward this long-term investigation, represented by this proposal, the investigators aim to comprehensively and globally describe the patterns of autoantibody expressions, the possible role in disease outcomes, and the relationship between these autoantibodies to tumor-specific/tumor-associated antigens by histologic examination as well as to peripheral immune characteristics in HCC patients with or without recurrence after surgery.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Doan Dao, MD · Johns Hopkins School of Medicine

  • Binh T Mai, MD, PhD · 108 Military Central Hospital, Hanoi, Viet Nam

  • Chi V Dang, MD, PhD · Johns Hopkins University

  • Heng Zhu, PhD · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-16
Primary Completion
2026-10-31
Completion
2026-12-31

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06141564 on ClinicalTrials.gov